AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)‘s stock had its “hold” rating reiterated by analysts at Cantor Fitzgerald in a research note issued to investors on Monday.

The analysts wrote, “AMAG announced the commercial launch of Intrarosa (DHEA vaginal insert) as a treatment for moderate to severe dyspareunia associated with vulvar vaginal atrophy (VVA).””

Several other brokerages also recently commented on AMAG. Jefferies Group LLC set a $40.00 target price on AMAG Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, April 20th. Barclays PLC reaffirmed a “hold” rating and issued a $25.00 target price on shares of AMAG Pharmaceuticals in a research report on Friday, May 5th. Zacks Investment Research raised AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 target price on the stock in a research report on Tuesday, July 11th. BidaskClub raised AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. Finally, Deutsche Bank AG set a $24.00 target price on AMAG Pharmaceuticals and gave the stock a “hold” rating in a research report on Friday, July 7th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $28.09.

Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) traded up 2.85% during midday trading on Monday, hitting $19.85. The company had a trading volume of 626,828 shares. The company’s market cap is $695.64 million. AMAG Pharmaceuticals has a 12 month low of $16.00 and a 12 month high of $36.83. The stock’s 50-day moving average price is $18.21 and its 200-day moving average price is $21.64.

AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings data on Tuesday, May 2nd. The specialty pharmaceutical company reported ($1.06) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.09 by $1.15. The firm had revenue of $139.47 million during the quarter, compared to analyst estimates of $150.32 million. AMAG Pharmaceuticals had a negative net margin of 5.61% and a positive return on equity of 1.69%. The company’s quarterly revenue was up 27.6% compared to the same quarter last year. During the same quarter last year, the company earned ($0.22) EPS. On average, equities research analysts forecast that AMAG Pharmaceuticals will post $5.40 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was reported by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2017/07/24/amag-pharmaceuticals-inc-nasdaqamag-earns-hold-rating-from-cantor-fitzgerald.html.

In related news, SVP Julie Krop sold 4,938 shares of the firm’s stock in a transaction on Thursday, July 13th. The stock was sold at an average price of $20.00, for a total transaction of $98,760.00. Following the completion of the sale, the senior vice president now directly owns 28,336 shares of the company’s stock, valued at approximately $566,720. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 3.80% of the company’s stock.

Several large investors have recently added to or reduced their stakes in AMAG. Comerica Bank raised its position in AMAG Pharmaceuticals by 5.1% in the fourth quarter. Comerica Bank now owns 36,399 shares of the specialty pharmaceutical company’s stock valued at $837,000 after buying an additional 1,764 shares in the last quarter. Dimensional Fund Advisors LP raised its position in AMAG Pharmaceuticals by 1.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 406,303 shares of the specialty pharmaceutical company’s stock valued at $14,140,000 after buying an additional 6,507 shares in the last quarter. Thrivent Financial for Lutherans raised its position in AMAG Pharmaceuticals by 5.8% in the fourth quarter. Thrivent Financial for Lutherans now owns 18,380 shares of the specialty pharmaceutical company’s stock valued at $640,000 after buying an additional 1,000 shares in the last quarter. Norges Bank bought a new position in AMAG Pharmaceuticals during the fourth quarter valued at about $19,914,000. Finally, Teachers Advisors LLC raised its position in AMAG Pharmaceuticals by 9.5% in the fourth quarter. Teachers Advisors LLC now owns 59,891 shares of the specialty pharmaceutical company’s stock valued at $2,084,000 after buying an additional 5,216 shares in the last quarter.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.